SecBot SecBot
PRESS-RELEASE ·Filed May 21, 2026

OLMA

Olema Oncology
BULLISH
Impact 6/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The Phase 1 data are early but positive for a novel mechanism. Watch for ASCO presentation details on May 30 and any subsequent partnership or financing announcements. The stock may see volatility around the ASCO data release.

DirectionBullish
Confidencemedium
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.68
T+0 close · May 21, 2026 · via day close
Latest settled
−22.15%
T+60 · $10.65
Vs SPY
−25.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $13.68entry
  2. T+1 · 6mo ago −0.95%α −1.54% · $13.55
  3. T+5 · 6mo ago −7.09%α −8.77% · $12.71
  4. T+20 · 5mo ago −25.51%α −24.10% · $10.19
  5. T+60 · 3mo ago −22.15%α −25.34% · $10.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Olema Oncology announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability and early anti-tumor activity across solid tumors. The data will be presented at ASCO 2026. While the safety profile and tumor shrinkage in 13 of 19 evaluable patients are encouraging, the sample is small and heavily pretreated, limiting immediate commercial read-through.

Key Facts

  • OP-3136 monotherapy showed no dose-limiting toxicities and no discontinuations due to TRAEs across doses up to 45 mg/day.
  • Among 19 response-evaluable patients, tumor shrinkage was observed in 13 patients; 2 confirmed PRs and 1 unconfirmed PR.
  • Most common TRAEs were dysgeusia (81% any grade), anemia (38% any grade; 6% grade 3), and neutropenia (34% any grade; 28% grade 3).
  • 11 of 32 patients remain on treatment; longest treatment duration is 62 weeks.
  • Data will be presented at ASCO on May 30, 2026; a Phase 3 OPERA-02 trial-in-progress poster will also be presented.
  • OP-3136 is being evaluated in ER+/HER2- advanced breast cancer, mCRPC, and mNSCLC.

Financial Impact

No financial data provided; clinical-stage company with no approved products or revenue.

pipeline valueclinical development timeline

Risk Factors

  • Small sample size (32 patients, 19 evaluable) limits statistical reliability.
  • Grade 3 neutropenia (28%) and anemia (6%) may become dose-limiting in larger cohorts.
  • No revenue or near-term approval; company is pre-commercial and dependent on financing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3299773

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026